David Lebowitz
Stock Analyst at Citigroup
(4.30)
# 366
Out of 5,126 analysts
119
Total ratings
59.3%
Success rate
14.38%
Average return
Main Sectors:
Stocks Rated by David Lebowitz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IONS Ionis Pharmaceuticals | Maintains: Buy | $69 → $84 | $86.50 | -2.89% | 14 | Sep 3, 2025 | |
| CYTK Cytokinetics | Maintains: Buy | $77 → $84 | $62.34 | +34.74% | 4 | Sep 2, 2025 | |
| CLDX Celldex Therapeutics | Maintains: Buy | $56 → $48 | $23.83 | +101.43% | 2 | Aug 20, 2025 | |
| SDGR Schrödinger | Downgrades: Neutral | $35 → $20 | $13.49 | +48.26% | 10 | Aug 15, 2025 | |
| ASND Ascendis Pharma | Maintains: Buy | $243 → $290 | $222.15 | +30.54% | 14 | Aug 8, 2025 | |
| INCY Incyte | Maintains: Buy | $88 → $103 | $108.39 | -4.97% | 6 | Jul 30, 2025 | |
| VKTX Viking Therapeutics | Maintains: Neutral | $31 → $38 | $28.44 | +33.61% | 2 | Jul 24, 2025 | |
| COGT Cogent Biosciences | Maintains: Buy | $15 → $22 | $37.08 | -40.67% | 4 | Jul 18, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Buy | $58 → $67 | $68.05 | -1.54% | 5 | Jul 11, 2025 | |
| EXEL Exelixis | Maintains: Buy | $45 → $56 | $43.90 | +27.56% | 3 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $14 → $10 | $12.28 | -18.57% | 8 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $4 → $1.5 | $1.14 | +31.58% | 6 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $32 → $45 | $74.68 | -39.74% | 4 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $65 → $68 | $100.47 | -32.32% | 4 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $382 | $477.60 | -20.02% | 1 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $103 → $96 | $58.13 | +65.15% | 3 | Jun 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $18 → $12 | $4.93 | +143.41% | 2 | Jul 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $170 → $164 | $328.16 | -50.02% | 7 | Jul 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $36 → $39 | $27.32 | +42.75% | 6 | Jun 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $20 → $21 | $21.01 | -0.05% | 11 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $435 → $405 | $6.26 | +6,369.65% | 1 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $13 → $14 | $4.56 | +207.02% | 2 | Oct 12, 2021 |
Ionis Pharmaceuticals
Sep 3, 2025
Maintains: Buy
Price Target: $69 → $84
Current: $86.50
Upside: -2.89%
Cytokinetics
Sep 2, 2025
Maintains: Buy
Price Target: $77 → $84
Current: $62.34
Upside: +34.74%
Celldex Therapeutics
Aug 20, 2025
Maintains: Buy
Price Target: $56 → $48
Current: $23.83
Upside: +101.43%
Schrödinger
Aug 15, 2025
Downgrades: Neutral
Price Target: $35 → $20
Current: $13.49
Upside: +48.26%
Ascendis Pharma
Aug 8, 2025
Maintains: Buy
Price Target: $243 → $290
Current: $222.15
Upside: +30.54%
Incyte
Jul 30, 2025
Maintains: Buy
Price Target: $88 → $103
Current: $108.39
Upside: -4.97%
Viking Therapeutics
Jul 24, 2025
Maintains: Neutral
Price Target: $31 → $38
Current: $28.44
Upside: +33.61%
Cogent Biosciences
Jul 18, 2025
Maintains: Buy
Price Target: $15 → $22
Current: $37.08
Upside: -40.67%
BridgeBio Pharma
Jul 11, 2025
Maintains: Buy
Price Target: $58 → $67
Current: $68.05
Upside: -1.54%
Exelixis
May 15, 2025
Maintains: Buy
Price Target: $45 → $56
Current: $43.90
Upside: +27.56%
May 9, 2025
Maintains: Neutral
Price Target: $14 → $10
Current: $12.28
Upside: -18.57%
Mar 4, 2025
Maintains: Neutral
Price Target: $4 → $1.5
Current: $1.14
Upside: +31.58%
Feb 12, 2025
Maintains: Sell
Price Target: $32 → $45
Current: $74.68
Upside: -39.74%
Nov 13, 2024
Maintains: Buy
Price Target: $65 → $68
Current: $100.47
Upside: -32.32%
Mar 6, 2024
Initiates: Buy
Price Target: $382
Current: $477.60
Upside: -20.02%
Jun 30, 2023
Maintains: Neutral
Price Target: $103 → $96
Current: $58.13
Upside: +65.15%
Jul 15, 2022
Maintains: Equal-Weight
Price Target: $18 → $12
Current: $4.93
Upside: +143.41%
Jul 15, 2022
Maintains: Equal-Weight
Price Target: $170 → $164
Current: $328.16
Upside: -50.02%
Jun 7, 2022
Maintains: Overweight
Price Target: $36 → $39
Current: $27.32
Upside: +42.75%
Oct 12, 2021
Maintains: Equal-Weight
Price Target: $20 → $21
Current: $21.01
Upside: -0.05%
Oct 12, 2021
Maintains: Overweight
Price Target: $435 → $405
Current: $6.26
Upside: +6,369.65%
Oct 12, 2021
Maintains: Equal-Weight
Price Target: $13 → $14
Current: $4.56
Upside: +207.02%